Melquin-3 Topical Solution
FDA Issues Proposal to Increase Consumer Awareness of Tanning Bed Risks »
"Today, the U.S. Food and Drug Administration issued a proposed order that, if finalized, would reclassify sunlamp products and require labeling to include a recommendation designed to warn young people not to use these devices.
Accordin"...
Read the FDA Issues Proposal to Increase Consumer Awareness of Tanning Bed Risks article »
Melquin-3 Topical Solution
CLINICAL PHARMACOLOGY
Topical application of hydroquinones produce a reversible depigmentation of the skin by the inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (DOPA) [Denton, C., et al, 1952 (1)] and supression of other melanocyte metabolic processes [Jimbow, K., et al, 1974 (2)]. Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas [Parrish, J., et al, 1978 (3)].
Last reviewed on RxList: 1/20/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Melquin-3 Topical Solution Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Skin & Beauty
Get beauty tips and body treatments.
Updated & New
